A solid-phase immunoadsorbent assay for serum prostatic acid phosphatase.
A solid-phase immunoadsorbent assay for serum prostatic acid phosphatase (PAP) measurement has been developed as modified from our previously reported immunofluoroassay, utilizing the specific anti-PAP antibodies conjugated to CNBr-activated Sepharose 4B. The serum prostatic acid phosphatase was bound, and separated from other acid phosphatases and serum proteins, by the solid-phase anti-PAP IgG Sepharose 4B. The enzyme activity was quantitated by measuring the enzyme hydrolytic product, alpha-naphthol, from a primary standard solution. The entire procedure could be performed within four hours. The sensitivity of this method was 0.22 I.U./l of enzyme activity or 0.88 ng of prostatic acic phosphatase protein per ml of serum. Normal range of serum prostatic acid phosphatase as determined by this assay was found to be 0.4--2.4 I.U./l of enzyme activity (or 1.60--9.60 ng of enzyme protein per ml of serum). Initial clinical evaluation showed that 19 of 25 patients with early stages of prostatic cancer and 12 of 14 patients with metastatic prostatic cancer exhibited an elevated enzyme level (overall 79%), as compared with only six and eight patients, respectively (overall 36%), by a conventional chemical method.
D000135:Acid Phosphatase / Q000097:blood*; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000201:enzymology; D005260:Female; D006801:Humans; D007118:Immunoassay; D008175:Lung Neoplasms / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000201:enzymology*; D011467:Prostate / Q000201:enzymology*; D011471:Prostatic Neoplasms / Q000201:enzymology*; D012016:Reference Values
D000135:Acid Phosphatase